🎯 LOT Newcomer Limited-Time Airdrop is Live!
Individual users can earn up to 1,000 LOT — share from a total prize pool of 1,000,000 LOT!
🏃 Join now: https://www.gate.com/campaigns/1294
Complete deposit and trading tasks to receive random LOT airdrops. Exclusive Alpha trading task await!🎯 LOT Newcomer Limited-Time Airdrop is Live!
Individual users can earn up to 1,000 LOT — share from a total prize pool of 1,000,000 LOT!
🏃 Join now: https://www.gate.com/campaigns/1294
Complete deposit and trading tasks to receive random LOT airdrops. Exclusive Alpha trading task await!
$HIMS #HIMS
Novo Nordisk discontinues partnership with Hims & Hers over Wegovy sale
Jun. 23, 2025
Novo Nordisk (NVO) said on Monday that it will cease its partnership with Hims & Hers Health (NYSE:HIMS), ending the direct access to Wegovy, its weight loss drug, through NovoCare Pharmacy.
In late April, the FDA declared that the Wegovy shortage had been resolved. Post that, Novo Nordisk began collaborating with telehealth companies including Hims & Hers for direct access to its obesity treatment injection.
However, after more than a month of working together, Novo Nordisk said that Hims & Hers Health has not complied with legal regulations that prohibit the mass sale of compounded drugs under the misleading notion of “personalization”, raising concerns about patient safety.
“We will collaborate with telehealth companies that prioritize patient safety in providing direct access to Wegovy. If companies engage in illegal compounding practices that threaten the health of Americans, we will take appropriate action.” Dave Moore, Executive Vice President, US Operations of Novo Nordisk said in a statement.
The shares of Hims & Hers is down 24% premarket post this news.
Novo Nordisk mentioned that an investigation showed that counterfeit semaglutide drugs sold by telehealth providers and compounding pharmacies contain active pharmaceutical ingredients sourced from unapproved foreign suppliers in China.